MedTrace Logo

Impact of Propranolol Strategies on Myocardial Injury After Breast Cancer Surgery

NCT07583134 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-15

No results posted yet for this study

Summary

This study aims to evaluate the impact of using propranolol, a non-selective beta-blocker, on preventing myocardial injury after non-cardiac surgery (MINS) in breast cancer patients who also have hypertension or angina. Stress from surgery and anesthesia can increase sympathetic activity and inflammation, which may lead to heart stress. This pragmatic clinical trial will compare patients who are prescribed propranolol as part of their routine care with those who are not. Researchers will analyze blood samples and surgical tissues collected during normal treatment to observe changes in heart health and the tumor microenvironment.

Conditions

  • Breast Cancer
  • Myocardial Injury After Noncardiac Surgery (MINS)

Interventions

DRUG

propranolol

Propranolol (dosage based on clinical indication) for at least 14 days before surgery until the morning of the operation.

OTHER

Usual Care

Standard medical management (e.g., CCB, ACEi, ARB, or diuretics) at the physician's discretion, excluding beta-blockers.

Sponsors & Collaborators

  • Seoul St. Mary's Hospital

    collaborator OTHER

  • Chang-Ik Yoon

    lead OTHER

Principal Investigators

  • Chang Ik Yoon, MD, Ph.D. · Seoul St. Mary's Hospital, The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-26
Primary Completion
2028-05-23
Completion
2033-05-24

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07583134 on ClinicalTrials.gov